First Risperdal Trial Ends With $2.5 Million Verdict Against J&J

First Risperdal Trial Ends With $2.5 Million Verdict Against J&J

A Philadelphia jury returned a $2.5 million verdict against healthcare giant Johnson & Johnson for a 20-year-old autistic man from Alabama who allegedly developed large breasts as a teenager while prescribed the antipsychotic medication Risperdal. The lawsuit charged that Johnson & Johnson failed to warn consumers of the distressing side effects that Risperdal causes, concealing from officials the dangerous and defective risks involved when taking the prescribed medication.

[Read more…]

Prescription Drug Risperdal Linked to Abnormal Male Breast Development

Attorney Wendy R. Fleishman of the national plaintiffs’ law firm Lieff Cabraser Heimann & Bernstein, LLP, announced that four young men prescribed the antipsychotic medication Risperdal recently filed separate personal injury lawsuits alleging that Risperdal is a defective and dangerous prescription drug. The complaints were brought against Johnson & Johnson and its subsidiary Janssen Pharmaceuticals, the manufacturer of Risperdal, in state court in Pennsylvania, where Janssen Pharmaceuticals is located. [Read more…]

Patients Charge Benicar is a Dangerous and Defective Drug

Attorney Lexi Hazam of the national plaintiffs’ law firm Lieff Cabraser Heimann & Bernstein, LLP, announced that two patients prescribed olmesartan medoxomil, a widely-prescribed medication sold under the brand name Benicar, today filed a personal injury lawsuit alleging that Benicar is a dangerous and defective drug. The complaint, filed in federal court in San Francisco, names as defendants Japanese-based Daiichi Sankyo, Benicar’s manufacturer, and Forest Laboratories, which marketed Benicar in the U.S. Steven W. Teppler of the Abbott Law Group, P.A. from Jacksonville, Florida, also serves as counsel for plaintiffs. [Read more…]

Xarelto Blood Thinner Lawsuits Consolidated in Louisiana Federal Court

Patients Allege Xarelto Linked to Serious Bleeding Risk

Wendy R. Fleishman of the national plaintiffs’ law firm Lieff Cabraser Heimann & Bernstein, LLP, announced today that nearly two dozen lawsuits filed against Johnson & Johnson subsidiary Janssen Pharmaceuticals and Bayer Corp. over the blood thinner Xarelto have been consolidated in Louisiana federal court. The U.S. Judiciary Panel on Multidistrict Litigation found that the cases have enough common complaints to warrant centralization. Xarelto has been linked to serious side effects including gastrointestinal bleeding, brain bleeding, other internal bleeds, and death. [Read more…]

Public Justice and AAJ Contest Dismissal of Big-Pharma Fraud Case

Public Justice and AAJ Contest Dismissal of Big-Pharma Fraud Case

Public Justice (represented by Lieff Cabraser) and the American Association for Justice today filed an amicus brief in the U.S. Court of Appeals for the Second Circuit urging the reinstatement of civil RICO claims that Sanofi-Aventis profited from a scheme to market and sell its antibiotic Ketek by falsely representing the drug’s safety — and concealing its risk of severe liver damage — from the FDA, doctors, and purchasers.

[Read more…]

Actos Bladder Cancer Lawsuit Video

Actos drug imagePatients who developed bladder cancer after being prescribed the diabetes medication Actos (brand name for the drug pioglitazone) have filed lawsuits against the manufacturer of Actos charging that it did not adequately warn of its cancer risks. Drug makers have a duty to warn of all serious side effects from their medications. These videos discuss the link between Actos and bladder cancer and summarize the charged made in the Actos bladder cancer lawsuits.

[Read more…]

Federal Jury Awards Punitive Damages In Actos Bladder Cancer Trial

Federal Jury Awards Punitive Damages in Actos Trial

A federal jury in Louisiana yesterday ordered Takeda Pharmaceutical Company and Eli Lilly & Company to pay $1,475,000 in compensatory damages, finding that they failed to adequately warn about bladder-cancer risks of their diabetes medicine Actos. Jurors also found that Takeda and Lilly executives acted with wanton and reckless disregard for patient safety in their handling of the drug, and awarded a total of $9 billion in punitive damages against both companies.

[Read more…]

Government and Manufacturers Slow to Respond to Manifest Tylenol Risks


Lawsuits are growing against the Johnson & Johnson Tylenol manufacturer McNeil for liver damage injuries alleged to have been caused by acetaminophen (Tylenol’s active ingredient). Businessweek notes that the suits accuse the company of making “conscious decisions not to redesign, re-label, warn, or inform the unsuspecting consuming public” about the dangers of the drug. [Read more…]

European Medicines Agency to Review Yaz Risks

Law360 reports that the European Medicines Agency (EMA) announced on Monday that it will meet in February 2013 to review the adverse side effects associated with third- and fourth-generation hormonal birth control pills such as Yaz. The EMA’s Pharmacovigilance Risk Assessment Committee will investigate whether to restrict later generation hormonal birth control pills, such as Yaz, to patients who are not able to take other contraceptives. [Read more…]

Attorney Paulina do Amaral Provides a Video Update on Yaz Birth Control Injury Lawsuits

Over $750 million to date has been paid out to women who developed blood clots and other serious side effects from Yaz, Yasmin, Gianvi, and Ocella birth control pills. All of these medications are manufactured by Bayer. To date, Bayer has settled 3,500 of these birth control drug injury lawsuits. [Read more…]